Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly Ceases Development of Alzheimer's Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Lilly Ceases Development of Alzheimer’s Drug

Eli Lilly and Co. will stop development of semagacestat, a gamma secretase inhibitor in Phase III development as a potential treatment for Alzheimer's disease.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Eli Lilly and Co. will stop development of semagacestat, a gamma secretase inhibitor in Phase III development as a potential treatment for Alzheimer’s disease. Two ongoing Phase III studies showed the drug did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform daily activities.

In the two Phase III trials, semagacestat was compared with placebo in more than 2,600 patients with mild-to-moderate Alzheimer’s disease. This interim analysis showed that cognition and the ability to complete activities of daily living of placebo-treated patients worsened, as expected. However, patients treated with semagacestat worsened to a greater degree than those treated with placebo. In addition, data showed semagacestat is associated with an increased risk of skin cancer compared with those who received placebo.

“This is disappointing news for the millions of Alzheimer’s patients and their families worldwide who anxiously await a successful treatment for this devastating illness,” said Jan M. Lundberg, Ph.D., executive vice president, Science and Technology, and President, Lilly Research Laboratories. “This is a setback, but Lilly’s commitment to beating Alzheimer’s will not waver.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters